Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan medoxomil and amlodipine besylate combination vs monotherapy in mild-to-moderate essential hypertension
2022-002539-79Phase 3Completed
- Sponsor
- Celltrion
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension and hypertensive heart disease comparing Azilsartan medoxomil + amlodipine besylate combination, Azilsartan medoxomil monotherapy and Amlodipine besylate monotherapy (3 arms). Started Sep 2022; status: completed.
02
Drugs
azilsartan medoxomilamlodipine
03
Conditions
essential hypertensionhypertensive heart disease
Beyond the preview
Go deeper on 2022-002539-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002539-79.